cll: btk inhibitors in hematologic oncology pathways - pathway-guided choices
Published 3 years ago • 704 plays • Length 35:31Download video MP4
Download video MP3
Similar videos
-
6:30
cll whiteboard #1: introduction & mechanisms of action of bcr signaling inhibitors
-
20:48
cll: btk inhibitors vs chemoimmunotherapy as initial treatment
-
21:31
bcr inhibitors in cll and lymphoma
-
16:58
chronic lymphocytic leukemia: treatment options for btki progressors
-
20:40
cll: treatment for btki progressors
-
1:32
selecting btk inhibitors for patients with mcl
-
2:53
btk inhibitors in cll
-
1:24
sequencing of btk inhibitors in cll
-
5:44
acalabrutinib versus ibrutinib for cll
-
0:48
dr. byrd on bruton's tyrosine kinase in chronic lymphocytic leukemia
-
5:13
key takeaways from the elevate-tn trial in cll
-
1:41
treating high risk cll with btk inhibitors
-
2:45
btk inhibition review in immune-mediated dermatological conditions
-
25:17
what to do after btki therapy fails
-
2:41
current and potential pi3k and btk inhibitors for cll
-
3:58
btk-targeted therapy for cll
-
1:14
evaluating the role of btk inhibitors in cll
-
1:05
btk degraders in the treatment of cll
-
1:17
dr. woyach on btk inhibition and the mechanism of action of ibrutinib